Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
single dose · 1 trial · 1 indication
Fasting serum chemistry, fasting hematology, fasting coagulation, fasting LFTs, fasting lipid panel, fasting glycemic assessment, urinalysis will be assessed.
| Arm | Type | Description |
|---|---|---|
| 25mg | OTHER | Subjects will be randomized in a 6:2 ratio to receive either the investigational drug or placebo |
| 75mg | OTHER | Subjects will be randomized in a 6:2 ratio to receive either the investigational drug or placebo |
| 150mg | OTHER | Subjects will be randomized in a 6:2 ratio to receive either the investigational drug or placebo |
| 300 mg | OTHER | Subjects will be randomized in a 6:2 ratio to receive either the investigational drug or placebo |
| 600 mg | OTHER | Subjects will be randomized in a 6:2 ratio to receive either the investigational drug or placebo |
| Name | Type | Description |
|---|---|---|
| Subcutaneous (SC) single dose | DRUG | all administered via subcutaneous injection. |
Inclusion Criteria: * 1\. Aged 18 to 60 years (inclusive) at the time of signing the informed consent form (ICF), male or female. 2\. Generally good health, with no clinically significant abnormalities in vital signs, physical examination, laboratory tests, or 12-lead ECG results at screening. ...
Single dose is an investigational drug being studied for the treatment of hypertension (HTN). It is currently in Phase 1 clinical development, with a completed trial evaluating its safety and tolerability in healthy adult subjects.
Single dose is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research on this investigational drug for hypertension.
Single dose is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under study for hypertension.
Single dose has one completed clinical trial, identified as NCT07529600, titled "A Phase I Clinical Study of ART101 Injection in Healthy Adult Subjects." This trial enrolled 40 participants in China and evaluated the drug in healthy volunteers.
Yes, single dose is also known as ART101. The completed Phase 1 clinical trial for this drug is titled "A Phase I Clinical Study of ART101 Injection in Healthy Adult Subjects," confirming that ART101 is the alternative name for single dose.